A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

ObesityOverweight

Interventions

DRUG

Orforglipron

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (4)

Clinical Pharmacology of Miami, Miami

Ohio Clinical Trials, Columbus

Axis, Dilworth

Endeavor Clinical Trials, San Antonio

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06824051 - A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight | Biotech Hunter | Biotech Hunter